Lumida
/LYRA
⌘K
Lyra Therapeutics Inc

Lyra Therapeutics Inc

LYRA
$0.20USD+5.26%+0.01 today

MARKET CAP

354,976

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$9
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$285,000$1.4M$1.6M$1.5M$398,000
YoY %+378.2%+14.3%-1.5%-74.1%
P / Sales198.7x68.5x166.2x8.8x12.0x
EV / Sales110.3x66.1x186.0x18.0x89.7x
Gross Profit, Adj.$285,000$1.4M$1.6M$1.5M$398,000
YoY %+378.2%+14.3%-1.5%-74.1%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit110.3x66.1x186.0x18.0x89.7x
EBITDA, Adj.$-42.6M$-53.9M$-65.3M$-60.3M$-29.1M
YoY %-92.7%-26.5%-21.0%+7.6%+51.7%
Margin %-14952.3%-3956.2%-4188.1%-3928.4%-7310.1%
EV / EBITDA-0.7x-1.7x-4.4x-0.5x-1.2x
EBIT$-43.6M$-56.3M$-67.1M$-96.3M$-31.0M
YoY %-96.4%-29.1%-19.2%-43.5%+67.8%
Margin %-15303.5%-4131.0%-4308.1%-6280.8%-7794.5%
EV / EBIT-0.7x-1.6x-4.3x-0.3x-1.2x
Net Income$-43.5M$-55.3M$-62.7M$-93.4M$-28.9M
YoY %-95.6%-27.0%-13.4%-49.1%+69.0%
Net Margin-15267.7%-4055.6%-4023.1%-6090.9%-7266.1%
EPS (GAAP)-$167.50-$91.50-$63.00-$71.75-$18.62
YoY %-29.3%+45.4%+31.1%-13.9%+74.0%